Literature DB >> 21483441

Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study.

A K Mitra, K Crews, S Pounds, X Cao, J R Downing, S Raimondi, D Campana, R C Ribeiro, J E Rubnitz, J K Lamba.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21483441      PMCID： PMC3238383          DOI： 10.1038/leu.2011.74

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

1.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba; Gary Dahl; Raul C Ribeiro; W Paul Bowman; Jeffrey Taub; Stanley Pounds; Bassem I Razzouk; Norman J Lacayo; Xueyuan Cao; Soheil Meshinchi; Barbara Degar; Gladstone Airewele; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; James R Downing; Wing Leung; Ching-Hon Pui; Dario Campana
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

2.  Emerging role of FKBP51 in AKT kinase/protein kinase B signaling.

Authors:  Huadong Pei; Zhenkun Lou; Liewei Wang
Journal:  Cell Cycle       Date:  2010-01-09       Impact factor: 4.534

3.  Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.

Authors:  Jatinder K Lamba; Kristine R Crews; Stanley B Pounds; Xueyuan Cao; Varsha Gandhi; William Plunkett; Bassem I Razzouk; Vishal Lamba; Sharyn D Baker; Susana C Raimondi; Dario Campana; Ching-Hon Pui; James R Downing; Jeffrey E Rubnitz; Raul C Ribeiro
Journal:  Pharmacogenomics       Date:  2011-03       Impact factor: 2.533

4.  FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.

Authors:  Huadong Pei; Liang Li; Brooke L Fridley; Gregory D Jenkins; Krishna R Kalari; Wilma Lingle; Gloria Petersen; Zhenkun Lou; Liewei Wang
Journal:  Cancer Cell       Date:  2009-09-08       Impact factor: 31.743

5.  The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.

Authors:  Umesh K Jinwal; John Koren; Sergiy I Borysov; Andreas B Schmid; Jose F Abisambra; Laura J Blair; Amelia G Johnson; Jeffrey R Jones; Cody L Shults; John C O'Leary; Ying Jin; Johannes Buchner; Marc B Cox; Chad A Dickey
Journal:  J Neurosci       Date:  2010-01-13       Impact factor: 6.167

6.  Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression.

Authors:  Liang Li; Brooke Fridley; Krishna Kalari; Gregory Jenkins; Anthony Batzler; Stephanie Safgren; Michelle Hildebrandt; Matthew Ames; Daniel Schaid; Liewei Wang
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

Review 7.  The role of FKBP5 in cancer aetiology and chemoresistance.

Authors:  L Li; Z Lou; L Wang
Journal:  Br J Cancer       Date:  2010-11-30       Impact factor: 7.640
  7 in total
  13 in total

1.  Evaluating the role of admixture in cancer therapy via in vitro drug response and multivariate genome-wide associations.

Authors:  John Jack; Tammy M Havener; Howard L McLeod; Alison A Motsinger-Reif; Matthew Foster
Journal:  Pharmacogenomics       Date:  2015-08-28       Impact factor: 2.533

Review 2.  In vitro human cell line models to predict clinical response to anticancer drugs.

Authors:  Nifang Niu; Liewei Wang
Journal:  Pharmacogenomics       Date:  2015       Impact factor: 2.533

Review 3.  Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation.

Authors:  Heather E Wheeler; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2012-01       Impact factor: 2.533

4.  Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.

Authors:  Heather E Wheeler; Eric R Gamazon; Claudia Wing; Uchenna O Njiaju; Chidiamara Njoku; Robert Michael Baldwin; Kouros Owzar; Chen Jiang; Dorothy Watson; Ivo Shterev; Michiaki Kubo; Hitoshi Zembutsu; Eric P Winer; Clifford A Hudis; Lawrence N Shulman; Yusuke Nakamura; Mark J Ratain; Deanna L Kroetz; Nancy J Cox; Mary Eileen Dolan
Journal:  Clin Cancer Res       Date:  2012-11-30       Impact factor: 12.531

5.  Lymphoblastoid cell lines in pharmacogenomics: how applicable are they to clinical outcomes?

Authors:  Amy L Stark; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2013-04       Impact factor: 2.533

6.  Genetic and epigenetic variants contributing to clofarabine cytotoxicity.

Authors:  Michael T Eadon; Heather E Wheeler; Amy L Stark; Xu Zhang; Erika L Moen; Shannon M Delaney; Hae Kyung Im; Patrick N Cunningham; Wei Zhang; M Eileen Dolan
Journal:  Hum Mol Genet       Date:  2013-05-29       Impact factor: 6.150

Review 7.  Cancer pharmacogenomics: strategies and challenges.

Authors:  Heather E Wheeler; Michael L Maitland; M Eileen Dolan; Nancy J Cox; Mark J Ratain
Journal:  Nat Rev Genet       Date:  2012-11-27       Impact factor: 53.242

Review 8.  Extending the lymphoblastoid cell line model for drug combination pharmacogenomics.

Authors:  Adrian J Green; Benedict Anchang; Farida S Akhtari; David M Reif; Alison Motsinger-Reif
Journal:  Pharmacogenomics       Date:  2021-05-28       Impact factor: 2.638

Review 9.  Pharmacogenomics of chemotherapeutic susceptibility and toxicity.

Authors:  Erika L Moen; Lucy A Godley; Wei Zhang; M Eileen Dolan
Journal:  Genome Med       Date:  2012-11-30       Impact factor: 11.117

10.  Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma.

Authors:  Katarzyna A Ellsworth; Bruce W Eckloff; Liang Li; Irene Moon; Brooke L Fridley; Gregory D Jenkins; Erin Carlson; Abra Brisbin; Ryan Abo; William Bamlet; Gloria Petersen; Eric D Wieben; Liewei Wang
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.